Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript

Bausch + Lomb reported Q1 revenue of $1.244 billion, up 6% constant currency, with adjusted EBITDA rising 59% to $200 million and margin expanding to 16.1%. Management raised 2026 revenue guidance by $45 million to $5.42 billion-$5.52 billion and lifted adjusted EBITDA guidance by $10 million to $1.01 billion-$1.06 billion, citing broad-based growth in Vision Care, Pharmaceuticals, and premium Surgical products. Key positives included Miebo revenue up 33%, Xiidra up 30%, LUMIFY up 15%, and premium IOL growth of 27%, partially offset by temporary Surgical weakness from weather and field-force rebuilding.

Analysis

BLCO’s print is less about a single-quarter beat than a visible inflection in mix quality: the company is finally converting top-line growth into disproportionate EBITDA expansion, which matters for a levered balance sheet business where every 100 bps of margin improvement has outsized equity value impact. The market is likely still underestimating how much of this is structurally self-help versus cyclical demand, because the operating leverage is coming from a lower fixed-cost base, better commercial execution, and a higher share of premium products rather than just FX or one-time pull-forward.

The near-term winner set is clearly the premium ophthalmic ecosystem: premium IOLs, dry eye, and contact lens modalities that require a broader commercial footprint. A subtle second-order effect is that BLCO’s field-force rebuild and product cadence should pressure smaller, under-scaled competitors that rely on narrower portfolios and less surgeon/prescriber density; as BLCO broadens modality coverage, its reps can bundle more of the wallet share in each account, making share gains easier to defend once won. The flip side is that the surgical restart is not yet fully de-risked—procedure timing, reimbursement friction, and salesforce productivity are all variables that can lag the narrative by one to two quarters.

The contrarian angle is that consensus may be anchoring on script noise and underappreciating the revenue-vs-volume tradeoff. If management is deliberately sacrificing some TRx growth to improve net revenue and gross-to-net, that can look like deceleration on the surface while actually improving lifetime economics; the market could misread this for several quarters. The key question for the next 90–180 days is whether the second-half launch slate and field-force normalization are enough to keep EBITDA growing materially faster than revenue; if yes, equity de-rating risk should fade quickly, but if surgical execution stalls, the stock likely reverts to being treated as a low-quality healthcare roll-up again.

Key Decisions for Investors

• Go long BLCO on any post-earnings pullback over the next 1-2 weeks; thesis is that 2026 EBITDA revisions are still too low if operating leverage persists, with upside to margin multiple expansion over the next 2-3 quarters.
• Pair trade: long BLCO / short a slower-growing ophthalmic peer with more levered SG&A and less premium mix; use this to isolate execution and mix-expansion alpha rather than sector beta.
• Buy BLCO Jan-2027 call spreads on weakness; the setup is a 12-18 month re-rating if management proves the 19% EBITDA margin midpoint is conservative and surgical normalizes.
• Avoid chasing strength in the first 48 hours after the print; the better entry is after the market digests whether Q2 surgical normalization actually appears in weekly data.
• If owning BLCO equity, hedge with a tactical short-dated put spread ahead of the next quarterly read on surgical execution and reimbursement, because that is the highest-probability interruption to the margin story.